MX2022013825A - Peptidos que contienen un motivo de interaccion con pcna para el uso en el tratamiento del cancer solido. - Google Patents
Peptidos que contienen un motivo de interaccion con pcna para el uso en el tratamiento del cancer solido.Info
- Publication number
- MX2022013825A MX2022013825A MX2022013825A MX2022013825A MX2022013825A MX 2022013825 A MX2022013825 A MX 2022013825A MX 2022013825 A MX2022013825 A MX 2022013825A MX 2022013825 A MX2022013825 A MX 2022013825A MX 2022013825 A MX2022013825 A MX 2022013825A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- treatment
- peptides containing
- solid cancer
- interacting motif
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title 1
- 101150008755 PCNA gene Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 201000009030 Carcinoma Diseases 0.000 abstract 2
- 206010039491 Sarcoma Diseases 0.000 abstract 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 abstract 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000003442 weekly effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a composiciones farmacéuticas y métodos para el tratamiento de carcinomas y sarcomas. En particular, la invención proporciona una composición farmacéutica que comprende un péptido o una sal farmacéuticamente aceptable del mismo para su uso en el tratamiento de un carcinoma o un sarcoma en un sujeto humano, en donde el péptido comprende una secuencia de aminoácidos como se establece en la SEQ ID NO: 1 y un péptido de penetración celular y en donde la composición farmacéutica se administra sistémicamente al sujeto semanalmente para proporcionar una dosis del péptido de aproximadamente 15-65 mg/m2 de área de superficie corporal (BSA) por semana, que se calcula como la forma libre del péptido.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2006699.9A GB202006699D0 (en) | 2020-05-06 | 2020-05-06 | Dosage regimen |
| PCT/EP2021/060992 WO2021224068A1 (en) | 2020-05-06 | 2021-04-27 | Peptides containing a pcna interacting motif for use in the treatment of solid cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013825A true MX2022013825A (es) | 2023-01-30 |
Family
ID=71080458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013825A MX2022013825A (es) | 2020-05-06 | 2021-04-27 | Peptidos que contienen un motivo de interaccion con pcna para el uso en el tratamiento del cancer solido. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230165933A1 (es) |
| EP (1) | EP4146239A1 (es) |
| JP (1) | JP2023524558A (es) |
| KR (1) | KR20230006581A (es) |
| AU (1) | AU2021268075A1 (es) |
| CA (1) | CA3177156A1 (es) |
| GB (1) | GB202006699D0 (es) |
| IL (1) | IL297933A (es) |
| MX (1) | MX2022013825A (es) |
| WO (1) | WO2021224068A1 (es) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3925542A1 (de) | 1989-08-02 | 1990-02-15 | Kallos Verlag Und Versand Gmbh | Glueckwunschkarte |
| US5534110A (en) | 1993-07-30 | 1996-07-09 | Lam Research Corporation | Shadow clamp |
| FR2739621B1 (fr) | 1995-10-05 | 1997-12-05 | Centre Nat Rech Scient | Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives |
| AU1818299A (en) | 1997-12-10 | 1999-06-28 | Washington University | Anti-pathogen system and methods of use thereof |
| GB9814527D0 (en) | 1998-07-03 | 1998-09-02 | Cyclacel Ltd | Delivery system |
| EP1958961A3 (en) | 1998-11-13 | 2008-09-03 | Cyclacel Limited | Transport Vectors |
| FR2849603B1 (fr) | 2003-01-07 | 2006-09-08 | Centre Nat Rech Scient | Composition pour le transport intracellulaire de macromolecules ou particules biologiques |
| GB0803352D0 (en) | 2008-02-22 | 2008-04-02 | Ntnu Technology Transfer As | Oligopeptidic compounds and uses thereof |
| GB201319621D0 (en) | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Antimicrobial agents and their use in therapy |
| GB201507722D0 (en) | 2015-05-06 | 2015-06-17 | Norwegian Univ Sci & Tech Ntnu | Anti-bacterial agents and their use in therapy |
| GB201507721D0 (en) | 2015-05-06 | 2015-06-17 | Norwegian Univ Sci & Tech Ntnu | Immunosuppressive agents and their use in therapy |
-
2020
- 2020-05-06 GB GBGB2006699.9A patent/GB202006699D0/en not_active Ceased
-
2021
- 2021-04-27 EP EP21722803.0A patent/EP4146239A1/en active Pending
- 2021-04-27 AU AU2021268075A patent/AU2021268075A1/en active Pending
- 2021-04-27 CA CA3177156A patent/CA3177156A1/en active Pending
- 2021-04-27 KR KR1020227042621A patent/KR20230006581A/ko active Search and Examination
- 2021-04-27 IL IL297933A patent/IL297933A/en unknown
- 2021-04-27 JP JP2022567486A patent/JP2023524558A/ja active Pending
- 2021-04-27 WO PCT/EP2021/060992 patent/WO2021224068A1/en unknown
- 2021-04-27 MX MX2022013825A patent/MX2022013825A/es unknown
- 2021-04-27 US US17/922,882 patent/US20230165933A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023524558A (ja) | 2023-06-12 |
| IL297933A (en) | 2023-01-01 |
| WO2021224068A1 (en) | 2021-11-11 |
| US20230165933A1 (en) | 2023-06-01 |
| GB202006699D0 (en) | 2020-06-17 |
| KR20230006581A (ko) | 2023-01-10 |
| AU2021268075A1 (en) | 2022-12-08 |
| EP4146239A1 (en) | 2023-03-15 |
| CA3177156A1 (en) | 2021-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7410948B2 (en) | Analogs of parathyroid hormone | |
| KR101445910B1 (ko) | 항종양 활성을 가지는 나노펩티드 | |
| KR100699422B1 (ko) | 부갑상선 호르몬의 동족체 | |
| US6921750B2 (en) | Analogs of parathyroid hormone | |
| NO169291C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktivt tetrapyrrol-amino-dicarboxylsyreaddukt | |
| HU213098B (en) | Process for producing decapeptides antagonistic to hormone for releazing lutheinizing-hormone and pharmaceutical compositions containing them as active components | |
| JP2511159B2 (ja) | 免疫欠損状態の治療のための医薬製剤 | |
| RU97107853A (ru) | Пептидная специфичность антител к мвр (миелиновому основному белку), содержащая его фармацевтическая композиция и способ лечения рассеянного склероза | |
| WO2003057820A2 (en) | Peptide activators of vegf | |
| RU2011133224A (ru) | Новые фармацевтические композиции | |
| MX2022013825A (es) | Peptidos que contienen un motivo de interaccion con pcna para el uso en el tratamiento del cancer solido. | |
| AU2001294024C1 (en) | Treatment of cancers by aplidine in conjunction with a myoprotector | |
| AU2001294024A1 (en) | Treatment of cancers by aplidine in conjunction with a myoprotector | |
| CA2465667A1 (en) | New peptides - analogs of human growth hormone-releasing hormone | |
| AU2002365974A8 (en) | Alpha-fetoprotein peptides and uses thereof | |
| US6228841B1 (en) | Peptide derivatives | |
| EP0850950A1 (en) | Peptide derivatives | |
| RU99122954A (ru) | Пептидные фрагменты основного белка миелина, фармацевтические композиции на их основе и применение данных композиций для лечения рассеянного склероза | |
| US6218364B1 (en) | Fluorinated neurokinin A antagonists | |
| CA2511446A1 (en) | Synthetic peptide analogs for the treatment of cancer | |
| KR930012034A (ko) | 급성 췌장염 치료용 브래디키닌-길항제 | |
| WO2001087934A3 (en) | Treatment of neoplasia/transformation using a pituitary tumor transforming gene carboxy terminal peptides | |
| CA2390081A1 (en) | Modified viral surface proteins which bind to cells of tumor vasculature | |
| RU98101096A (ru) | Соединения, вызывающие выделение гормона роста |